wemakeyousoundb
hopefully not gimboid
potential massive derail so I replied in the idiot's own threadI don’t agree at all. I think he is a real idiot
potential massive derail so I replied in the idiot's own threadI don’t agree at all. I think he is a real idiot
bojo is a pretend idot deflecting from what is happening shocker
(sorry: not a dig at you supine, just my appraisal of the twat)
If this is the case, Pfizer and BioNTech expects "to be able to develop and produce a tailor-made vaccine against that variant in approximately 100 days, subject to regulatory approval".
TL;DR said:Some correlates of protection from infection for Moderna's COVID-19 vaccine have been determined. They could be used going forward to evaluate the potential of other vaccines and redesigned/multivalent vaccines targeting new variants of concern.
Moderna have greenlit an omicron/B.1.1.529 vaccine candidate, mRNA-1273.529. They expect to have it ready for clinical testing within 60-90 days.
Novavax have also already started work on an omicron targeted version of their vaccine and expect to have that ready for testing and potential manufacture within a few weeks.
Novavax developing vaccine that targets new COVID-19 variant
Novavax Inc said on Friday it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks.www.reuters.com
We find evidence for an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared to the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14-59 days after complete vaccination compared to 60 days and longer.
TL;DR said:This study confirms a lower vaccine effectiveness against infection by delta, beta and gamma variants, compared to alpha. This effect was largest early after complete vaccination (difference in risk was less significant beyond 59 days post-dose-two). It may suggest advantages in mixing vaccinations and choosing optimal timing intervals of doses.
However the Moderna CEO thinks it will take "months" to start shipping a new variant vaccine.Moderna have greenlit an omicron/B.1.1.529 vaccine candidate, mRNA-1273.529. They expect to have it ready for clinical testing within 60-90 days.
However the Moderna CEO thinks it will take "months" to start shipping a new variant vaccine.
COVID-19 vaccine makers start work on Omicron-tailored shots
BioNTech, Moderna and Johnson & Johnson are working on vaccines that specifically target Omicron in case their existing shots are not effective against the new coronavirus variant, the companies said on Monday.www.reuters.com
pre-experimental is the word on the streetYep, scaling up always takes a while. They're gonna need a lot of the stuff.
It will def come out fast enough for the anti-vaxxers to go ape shit about it being "completely untested", though.
pre-experimental is the word on the street
More commentary on this and thoughts on the limitations of use (ie prescribe only to high risk patients and mitigate risk for female patients who might be pregnant).Under-dosing mutagenic antivirals, such as molnupiravir (for example - due to missed doses, incomplete courses, or low initial drug penetrance at the site of action), may lead to sublethal mutagenesis and so accelerate within-host evolution of the virus, potentiating new variants of concern that enhance transmissibility or immune escape.
Details: 'Mutagenic antivirals: the evolutionary risk of low doses'
See also:
FDA advisory panel narrowly endorses Merck's oral Covid treatment pill, despite reduced efficacy and safety questions
The FDA's Antimicrobial Drugs Advisory Committee voted 13 to 10 to recommend emergency authorization of molnupiravir, an oral antiviral drug to fight Covid.www.cnbc.com
Novavax has initiated development of an Omicron-specific construct of its SARS-CoV-2 Spike protein (rS) antigen, currently in use in NVX-CoV2373. The initial steps required to manufacture an Omicron-specific spike are underway and GMP manufacturing in a commercial facility is anticipated in January 2022. Lab-based assessment of a new strain-matched nanoparticle vaccine will begin within a few weeks.
This research underlines how hybrid immunity significantly enhances immunoresponse affinity/avidity/breadth.Rapid production of Spike-reactive IgG was observed in the vaccinated group providing evidence of effective vaccine priming. Overall, potent cross-neutralizing activity against current SARS–CoV–2 variants of concern was observed in the BTI group compared to the infection group.
This research points to the potential complications of "over specialising" forthcoming vaccines, ie tuning them to one particularly troublesome VOC at the expensive of VOCs as yet unseen; degrees of original antigenic sin. A universal coronavirus vaccine needs to very carefully select antigens to optimise for cross-reactivity.Neutralization potency against VOCs changed with heterologous virus encounter and number of antigen exposures. Neutralization potency fell differentially depending on targeted VOCs over 5-months from the second vaccine dose. Heterologous combinations of spike encountered during infection and vaccination shape subsequent cross-protection against VOC, with implications for future-proof next-generation vaccines.
The indication is that the phenomenon of enhanced vaccine responses by infection, which has been reproducibly described by us and others, is less effective if the infection involves heterologous spike from a VOC.
Comment from Valneva:Phase 2 trial COV-BOOST results ... All vaccine boosters except VLA2001 raised antibody and neutralising immune responses...
It would be interesting to re-examine the neutralising activity of sera from these individuals after 3 and 6 months.
The setting in this study leads us to believe that COV-Boost does not allow any conclusions to be reached regarding the use of VLA2001 as a booster in a real-life setting.
Valneva believes it is likely that the short interval between the second shot and booster shot could have adversely impacted the results for VLA2001, given that a longer interval is generally required for inactivated vaccines.
- Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers
- Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection
- As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease
- The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022
(Very early) estimates of vaccine effectiveness against symptomatic COVID-19 due to the omicron/B.1.1.529 variant were made using a test negative case control study and compared to that due to delta/B.1.617.2, ie a real world epidemiological estimate, rather than a lab based neutralisation study. The final analysis included 56,439 delta and 581 omicron cases.The Variant Technical Group reviewed the available neutralisation data from published international and internal UK studies (UK Health Security Agency, University of Oxford). UK data will be published as soon as possible and cited here when available. Across 5 preliminary live virus studies (3 international and 2 UK), there was a 20- to 40-fold reduction in neutralising activity by Pfizer 2-dose vaccinee sera for Omicron compared to early pandemic viruses. There was at least 10 fold loss of activity when compared to Delta; in both UK studies this was over 20 fold. A greater reduction in activity was seen for AZ 2-dose sera, and for a high proportion of such sera, neutralising activity fell below the limit of quantification in the assay. An mRNA booster dose resulted in an increase in neutralising activity irrespective of primary vaccination type, including an increase in the proportion of samples that were above the limit of quantification. This is true regardless of which vaccine was used for the primary course. These data are from the early period after the booster and data are urgently required on the durability of neutralising activity.